Integrated Quantitative Investments LLC Acquires New Position in Sensus Healthcare, Inc. (NASDAQ:SRTS)

Integrated Quantitative Investments LLC acquired a new stake in Sensus Healthcare, Inc. (NASDAQ:SRTS) in the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 36,283 shares of the company’s stock, valued at approximately $251,000.

Other institutional investors have also modified their holdings of the company. IFP Advisors Inc bought a new position in Sensus Healthcare in the fourth quarter worth approximately $95,000. Geode Capital Management LLC lifted its holdings in shares of Sensus Healthcare by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock worth $849,000 after buying an additional 11,525 shares during the period. Virtu Financial LLC bought a new position in shares of Sensus Healthcare during the 4th quarter worth $189,000. XTX Topco Ltd increased its stake in shares of Sensus Healthcare by 76.0% during the third quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock valued at $183,000 after buying an additional 13,619 shares during the period. Finally, Sigma Planning Corp bought a new stake in shares of Sensus Healthcare in the fourth quarter valued at about $215,000. 25.30% of the stock is owned by hedge funds and other institutional investors.

Sensus Healthcare Stock Down 9.0 %

Shares of Sensus Healthcare stock opened at $4.46 on Friday. The company has a market cap of $73.57 million, a P/E ratio of 11.15 and a beta of 1.11. Sensus Healthcare, Inc. has a 52-week low of $3.09 and a 52-week high of $9.33. The firm’s 50 day moving average price is $5.42 and its 200-day moving average price is $6.51.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. As a group, equities research analysts forecast that Sensus Healthcare, Inc. will post 0.32 EPS for the current fiscal year.

Analyst Ratings Changes

SRTS has been the topic of several recent research reports. Lake Street Capital dropped their target price on shares of Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Sensus Healthcare in a research note on Friday.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.